Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma

Targeting MAPK pathway using a combination of BRAF and MEK inhibitors is an efficient strategy to treat melanoma harboring BRAF -mutation. The development of acquired resistance is inevitable due to the signaling pathway rewiring. Combining western blotting, immunohistochemistry, and reverse phase p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncogene 2021-09, Vol.40 (37), p.5590-5599
Hauptverfasser:	Wang, Beike, Zhang, Wei, Zhang, Gao, Kwong, Lawrence, Lu, Hezhe, Tan, Jiufeng, Sadek, Norah, Xiao, Min, Zhang, Jie, Labrie, Marilyne, Randell, Sergio, Beroard, Aurelie, Sugarman, Eric, Rebecca, Vito W., Wei, Zhi, Lu, Yiling, Mills, Gordon B., Field, Jeffrey, Villanueva, Jessie, Xu, Xiaowei, Herlyn, Meenhard, Guo, Wei
Format:	Artikel
Sprache:	eng
Schlagworte:	13 13/95 59 631/67/1059/2326 631/67/1813/1634 82/80 96/31 AKT protein Animals Apoptosis Apoptosis - drug effects Cancer Cell Biology Cell culture Cell cycle Cell Line, Tumor Cellular signal transduction Development and progression Drug resistance Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Gene mutations Genetic aspects Health aspects Human Genetics Humans Imidazoles - administration & dosage Imidazoles - pharmacology Immunohistochemistry Internal Medicine Intracellular signalling Kinases MAP kinase Mechanistic Target of Rapamycin Complex 1 - antagonists & inhibitors Mechanistic Target of Rapamycin Complex 1 - metabolism Medicine Medicine & Public Health MEK inhibitors Melanoma Melanoma - drug therapy Melanoma - genetics Melanoma - metabolism Melanoma - pathology Metastasis Mice Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors Mitogen-Activated Protein Kinase Kinases - metabolism MTOR Inhibitors - pharmacology MTOR Inhibitors - therapeutic use Mutants Mutation Oncology Oncology, Experimental Protein arrays Protein Kinase Inhibitors - pharmacology Protein kinases Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - genetics PTEN protein Quinolines - administration & dosage Quinolines - pharmacology Rapamycin Signal transduction Signal Transduction - drug effects Sirolimus - pharmacology TOR protein TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - metabolism Tumors Western blotting Xenograft Model Antitumor Assays Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!